[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Amryt Pharma\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100548636","a-study-to-assess-the-incidence-of-skin-cancers-in-patients-with-epidermolysis-bullosa-receiving-filsuvez-100548636",false,"NCT06423573","A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez","A Long-term Non-interventional Study to Assess the Incidence of Skin Malignancies in Patients With Dystrophic and Junctional Epidermolysis Bullosa Receiving Treatment With Filsuvez","FOSteR","Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of dystrophic EB or junctional EB\n\nExclusion Criteria:\n\n* None","ALL",{"count":19,"type":20},580,"ESTIMATED","OBSERVATIONAL","In patients with epidermolysis bullosa (EB), collagen does not form properly, so their skin is very fragile and blisters easily. Such patients are also at greatly increased risk of developing skin cancers. Filsuvez is a topical gel used to promote healing of skin lesions in patients with certain types of EB. In this observational study, patients with either dystrophic EB (DEB) or junctional EB (JEB) will receive standard of care treatment, whether Filsuvez or something else, and will be followed for up to 5 years. The main purpose is to see if the use of Filsuvez affects the likelihood of developing skin malignancies in these patient populations.",[24,25],"Epidermolysis Bullosa, Dystrophic","Epidermolysis Bullosa, Junctional",[27,28],"Filsuvez","Birch bark extract","RECRUITING","2025-09-18",{"date":32,"type":33},"2025-09-19","ACTUAL",{"date":35,"type":33},"2024-12-18",{"date":37,"type":20},"2032-08-01",{"name":39,"class":40},"Amryt Pharma","INDUSTRY",5,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":51},"100553344","phase-4-open-label-study-to-evaluate-metreleptin-in-patients-with-partial-lipodystrophy-100553344","NCT06484868","Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy","A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients With Partial Lipodystrophy","Inclusion Criteria:\n\n* Confirmed diagnosis of familial or acquired partial lipodystrophy\n\nExclusion Criteria:\n\n* Treatment with any Investigational Medicinal Product (IMP) within 6 months or 5 times the terminal half-life of the corresponding IMP, whichever is longer, before the screening visit.\n\nOther protocol defined inclusion\u002Fexclusion criteria apply","12 Years",{"count":51,"type":20},12,"INTERVENTIONAL",[54],"PHASE4","This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy",[57],"Partial Lipodystrophy",[59],"Metreleptin","2025-07-02",{"date":62,"type":33},"2025-07-03",{"date":64,"type":33},"2024-02-08",{"date":66,"type":20},"2028-02",{"name":39,"class":40},""]